Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Validea
Provider: Thomson Reuters Stock Report
Provider: Edison Investment Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc Reaffirms FY 2013; Issues Q1 2013 Revenue Guidance Below Analysts' Estimates

Thursday, 7 Mar 2013 04:01pm EST 

Emergent BioSolutions Inc reaffirmed it fiscal 2013 guidance and expects total revenue of $290 to $310 million. For first quarter of 2013, it expects total revenues of $40 to $50 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $301 million for fiscal 2013; revenue of $60 million for first quarter of 2013. 

Related Company News

Company Quote

-0.77 -2.67%
30 Jan 2015